SINGH, Ambrish, Mohammad Salman HUSSAIN, Sreelatha AKKALA, Jitka KLUGAROVÁ, Andrea POKORNÁ, Miloslav KLUGAR, E. Haydn WALTERS, Ingrid HOPPER, Julie A. CAMPBELL, Bruce TAYLOR and Benny ANTONY. Beta-adrenergic drugs and risk of Parkinson’s disease: A systematic review and meta-analysis. AGEING RESEARCH REVIEWS. CLARE: ELSEVIER IRELAND LTD, 2022, vol. 80, September 2022, p. 1-13. ISSN 1568-1637. Available from: https://dx.doi.org/10.1016/j.arr.2022.101670.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Beta-adrenergic drugs and risk of Parkinson’s disease: A systematic review and meta-analysis
Authors SINGH, Ambrish, Mohammad Salman HUSSAIN (356 India, belonging to the institution), Sreelatha AKKALA, Jitka KLUGAROVÁ (203 Czech Republic, belonging to the institution), Andrea POKORNÁ (203 Czech Republic, belonging to the institution), Miloslav KLUGAR (203 Czech Republic, belonging to the institution), E. Haydn WALTERS, Ingrid HOPPER, Julie A. CAMPBELL, Bruce TAYLOR and Benny ANTONY (guarantor).
Edition AGEING RESEARCH REVIEWS, CLARE, ELSEVIER IRELAND LTD, 2022, 1568-1637.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30230 Other clinical medicine subjects
Country of publisher Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 13.100
RIV identification code RIV/00216224:14110/22:00127142
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.arr.2022.101670
UT WoS 000841188700006
Keywords in English Beta-adrenoceptors; Beta-blockers; Beta -antagonist; Beta-agonist; Propranolol; Salbutamol; Parkinson ?s disease
Tags 14110611, 14119612, 14119613, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 14/11/2022 08:37.
Abstract
Background: Parkinson's Disease (PD) is a neurodegenerative disorder manifested by rest tremor, rigidity, bradykinesia, and postural instability. Recent pharmaco-epidemiological studies evaluating beta-adrenergic drug use and risk of PD have reported conflicting findings. Objectives: This systematic review and meta-analyses evaluate the association between beta-adrenergic (agonists and antagonists) drugs' use and PD. Methods: An electronic literature search of eight databases was performed from inception to July 2021 to identify pharmaco-epidemiological studies (case-control and cohort) reporting the risk of PD in beta-adrenergic users compared to non-users. We used the generic inverse variance method and RevMan (5.3.5) to estimate pooled adjusted risk ratios (aRRs) of PD using a random-effects model. Results: Of 3168 records, 15 studies (10 case-control; five cohort) with 6508,877 participants, including 87,011 PD cases, were included. In the pooled analysis (n = 10) including any beta-antagonist users, compared with nonusers, the aRR for PD was 1.19 (CI: 1.05,1.35); for any beta-agonist users (n = 8) aRR for PD was 0.87 (CI: 0.78,0.97). Propranolol users had a significantly increased risk of PD (aRR:1.91; CI:1.20,3.06), whereas salbutamol use was associated with reduced risk of PD (aRR:0.95; CI:0.92,0.99). Significant heterogeneity (I2 >87%) was observed, but the majority (n = 13) of the studies were of high quality, based on the JBI tool. Conclusions: Beta-antagonist use was associated with a modestly increased risk of PD, whereas beta-agonist use was associated with a modest decreased risk of PD. Future epidemiological studies should address the issues of protopathic bias and indirect association using appropriate epidemiological methods.
Links
EF18_053/0016952, research and development projectName: Postdoc2MUNI
LTC20031, research and development projectName: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic
Investor: Ministry of Education, Youth and Sports of the CR, INTER-COST
PrintDisplayed: 25/4/2024 19:45